StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
bluebird bio (BLUE) PT Raised to $85 at Leerink Partners
December 1, 2016 11:26 AM
Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and lowered his price target on bluebird bio (NASDAQ: BLUE) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
bluebird bio (BLUE) PT Raised to $87 at Maxim Group
December 1, 2016 11:45 AM
BTIG Affirms bluebird bio (BLUE) at 'Buy' Following bb2121 Phase 1 Data in r/r Multiple Myeloma
December 1, 2016 7:51 AM
bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 Data
December 1, 2016 7:47 AM
bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean Safety
December 1, 2016 6:18 AM
bluebird bio (BLUE) Reports Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate
November 30, 2016 5:28 PM